CAR-NK and using Interlukin-27 to boost the cytotoxic effect of NK cells on CLL in the bone marrow

[AussieNeil]

"A chimeric antigen receptor (CAR) construct using transduced natural killer cells instead of T cells was associated with a high complete remission rate without the cytokine release syndrome (CRS) frequently seen with CAR T cell therapy, early clinical trial results show.

:

..there were no cases of CRS, neurotoxicity, or GvHD and no increase over baseline in inflammatory cytokines, including interleukin-6, a key factor in the development and severity of CRS. The maximum tolerated dose was not reached." Given CAR-T doesn't work as well for CLL as it does for other cancers, CAR-NK may be a better option and I hope the reduced CRS, neurotoxicity etc, risks remain unobserved in expanded trials.

From Safer CAR uses modified NK cells for advanced CLL, NHL (from February 2020) mdedge.com/hematology-oncol...

In related news, Interleukin-27 increased cytotoxic effects of bone marrow NK cells in CLL.

Chronic lymphocytic leukemia is characterized by significant immune perturbation, including significant impairment of natural killer (NK) cells, which leads to disease complications and reduced effectiveness of treatment. (My emphasis)

However, the use of recombinant human interleukin-27 (IL-27) was able to increase cytotoxic effects of bone marrow natural killer cells in chronic lymphocytic leukemia (CLL).

mdedge.com/hematology-oncol...

This was an in vitro study, but I mention it because it highlights the importance of research into reconstituting our CLL compromised immune systems.

This is an unlocked post healthunlocked.com/cllsuppo...

Neil

[Sushibruno]

🙀😫 it sounds like cll is very complicated. Even with car. it's hard to understand this for me but this is what I got out of it😏

[Ernest2 in reply to Sushibruno]

Hi Sushi,

I think for the dummies amongst us we need cajunjeff to explain CAR treatment. It's a funny one because there is some very simplistic understanding, but in the last few years I think it had moved on a lot, and there is probably still a lot for the clinicians to learn.

Best wishes,

Ernest

[Sushibruno in reply to Ernest2]

Yes Ernest I agree, I was gonna say the same thing to Neil, I need Jeff to explained this in simple terms lol. Where are u Jeff. I understood some but not all. Im officially a cll dummy🤣.

[Ernest2]

Sounds like potential for good progress. Great that they keep pushing into new areas, and I like the idea of a second arm of therapy that corrects the immune system response.

Many thanks Neil,

Ernest